Home » Stocks » ZEAL

Zealand Pharma A/S (ZEAL)

Stock Price: $30.83 USD -0.19 (-0.60%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
Market Cap 1.44B
Revenue (ttm) 5.82M
Net Income (ttm) 89.15M
Shares Out 43.39M
EPS (ttm) -3.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $30.83
Previous Close $31.02
Change ($) -0.19
Change (%) -0.60%
Day's Open 31.25
Day's Range 30.83 - 31.32
Day's Volume 61,672
52-Week Range 27.90 - 44.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Company announcement – No. 37 / 20 2 1

1 week ago - GlobeNewsWire

C ompany a nnouncement – No. 36 / 202 1

2 weeks ago - GlobeNewsWire

C ompany a nnouncement – No. 32 / 202 1

3 weeks ago - GlobeNewsWire

Company announcement – No. 31/ 20 2 1

1 month ago - GlobeNewsWire

Zealand Pharma AS (ZEAL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

1 month ago - Zacks Investment Research

C ompany  a nnouncement – No.  29 / 202 1

1 month ago - GlobeNewsWire

Company announcement – No. 22 / 2021

2 months ago - GlobeNewsWire

Company announcement – No. 21/ 2021

2 months ago - GlobeNewsWire

A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.

2 months ago - The Motley Fool

Company announcement – No. 19/ 2021

2 months ago - GlobeNewsWire

Company announcement – No. 18/ 2021

2 months ago - GlobeNewsWire

Company announcement – No. 17 / 2020

2 months ago - GlobeNewsWire

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

Other stocks mentioned: BMY, PFE, BCRX, MRKR, PCRX, PRQR, RUBY
3 months ago - Benzinga

Company announcement – No. 14 / 2021

3 months ago - GlobeNewsWire

Company Announcement – No. 13 / 2021

3 months ago - GlobeNewsWire

Company announcement – No. 11/ 2021

3 months ago - GlobeNewsWire

Company announcement – No. 10 / 2021

3 months ago - GlobeNewsWire

Press Release – No. 7 / 2021

4 months ago - GlobeNewsWire

Company announcement – No. 4 / 2021

4 months ago - GlobeNewsWire

Company announcement – No. 1 / 2021

4 months ago - GlobeNewsWire

Company announcement – No. 64 / 2020

5 months ago - GlobeNewsWire

Company announcement – No. 60 / 2020

6 months ago - GlobeNewsWire

Company announcement – No. 59 / 2020

6 months ago - GlobeNewsWire

Company announcement – No. 57 / 2020

6 months ago - GlobeNewsWire

In this article we will take a look at whether hedge funds think Zealand Pharma A/S (NASDAQ:ZEAL) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving in...

6 months ago - Insider Monkey

Company announcement – No. 55 / 2020

7 months ago - GlobeNewsWire

Zealand Pharma A/S (ZLDPF) CEO Emmanuel Dulac on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

About ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; D... [Read more...]

Industry
Biotechnology
IPO Date
Aug 9, 2017
CEO
Emmanuel Dulac
Employees
335
Stock Exchange
NASDAQ
Ticker Symbol
ZEAL
Full Company Profile

Financial Performance

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price forecast is 38.61, which is an increase of 25.24% from the latest price.

Price Target
$38.61
(25.24% upside)
Analyst Consensus: Buy